Response of asymmetric dimethylarginine to hemodialysis-associated hypotension in end-stage renal disease patients

Botond Csiky, E. Sulyok, Orsolya Lakatos, I. Wittmann, Jens Martens-Lobenhoffer, Stefanie M. Bode-Böger

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aims: To define the role of asymmetric dimethylarginine (ADMA) in the control of blood pressure (BP) during hemodialysis (HD). Methods:L-Arginine, ADMA and symmetric dimethylarginine (SDMA) levels of patients with (n = 18) or without (n = 13) hypotensive episodes during HD sessions were measured before and after HD treatment by liquid chromatography-mass spectrometry. Clinical variables, laboratory parameters and underlying pathologies of end-stage renal disease (ESRD) were comparable in the groups. BP was serially recorded. Results: In patients with ESRD, plasma dimethylarginines were markedly elevated and decreased significantly by the end of the HD sessions. ADMA levels in patients having hypotensive episodes during HD were significantly higher than in those maintaining their BP (before HD: 0.62 ± 0.11 μmol/l vs. 0.71 ± 0.13 μmol/l, p = 0.04; after HD: 0.31 ± 0.11 μmol/l vs. 0.43 ± 0.11 μmol/l, p = 0.01). There was a significant inverse relationship of the minimum systolic and diastolic BP during HD to the predialysis ADMA levels (for systolic BP r = -0.50, p <0.01; for diastolic BP r = -0.59, p <0.01) and to the postdialysis ADMA levels (for systolic BP r = -0.49, p <0.01; for diastolic BP r = -0.51, p <0.005), respectively. Conclusions: It is suggested that excessive NO generation is involved in the HD-associated hypotension and induces an increase in plasma ADMA levels to prevent further fall in BP.

Original languageEnglish
JournalNephron - Clinical Practice
Volume108
Issue number2
DOIs
Publication statusPublished - Mar 2008

Fingerprint

Hypotension
Chronic Kidney Failure
Renal Dialysis
Blood Pressure
N,N-dimethylarginine
Liquid Chromatography
Arginine
Mass Spectrometry
Pathology

Keywords

  • Asymmetric dimethylarginine
  • Hypotension
  • Regular hemodialysis

ASJC Scopus subject areas

  • Nephrology

Cite this

Response of asymmetric dimethylarginine to hemodialysis-associated hypotension in end-stage renal disease patients. / Csiky, Botond; Sulyok, E.; Lakatos, Orsolya; Wittmann, I.; Martens-Lobenhoffer, Jens; Bode-Böger, Stefanie M.

In: Nephron - Clinical Practice, Vol. 108, No. 2, 03.2008.

Research output: Contribution to journalArticle

Csiky, Botond ; Sulyok, E. ; Lakatos, Orsolya ; Wittmann, I. ; Martens-Lobenhoffer, Jens ; Bode-Böger, Stefanie M. / Response of asymmetric dimethylarginine to hemodialysis-associated hypotension in end-stage renal disease patients. In: Nephron - Clinical Practice. 2008 ; Vol. 108, No. 2.
@article{343477947341418abfe0587603181476,
title = "Response of asymmetric dimethylarginine to hemodialysis-associated hypotension in end-stage renal disease patients",
abstract = "Aims: To define the role of asymmetric dimethylarginine (ADMA) in the control of blood pressure (BP) during hemodialysis (HD). Methods:L-Arginine, ADMA and symmetric dimethylarginine (SDMA) levels of patients with (n = 18) or without (n = 13) hypotensive episodes during HD sessions were measured before and after HD treatment by liquid chromatography-mass spectrometry. Clinical variables, laboratory parameters and underlying pathologies of end-stage renal disease (ESRD) were comparable in the groups. BP was serially recorded. Results: In patients with ESRD, plasma dimethylarginines were markedly elevated and decreased significantly by the end of the HD sessions. ADMA levels in patients having hypotensive episodes during HD were significantly higher than in those maintaining their BP (before HD: 0.62 ± 0.11 μmol/l vs. 0.71 ± 0.13 μmol/l, p = 0.04; after HD: 0.31 ± 0.11 μmol/l vs. 0.43 ± 0.11 μmol/l, p = 0.01). There was a significant inverse relationship of the minimum systolic and diastolic BP during HD to the predialysis ADMA levels (for systolic BP r = -0.50, p <0.01; for diastolic BP r = -0.59, p <0.01) and to the postdialysis ADMA levels (for systolic BP r = -0.49, p <0.01; for diastolic BP r = -0.51, p <0.005), respectively. Conclusions: It is suggested that excessive NO generation is involved in the HD-associated hypotension and induces an increase in plasma ADMA levels to prevent further fall in BP.",
keywords = "Asymmetric dimethylarginine, Hypotension, Regular hemodialysis",
author = "Botond Csiky and E. Sulyok and Orsolya Lakatos and I. Wittmann and Jens Martens-Lobenhoffer and Bode-B{\"o}ger, {Stefanie M.}",
year = "2008",
month = "3",
doi = "10.1159/000114451",
language = "English",
volume = "108",
journal = "Experimental Nephrology",
issn = "0028-2766",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Response of asymmetric dimethylarginine to hemodialysis-associated hypotension in end-stage renal disease patients

AU - Csiky, Botond

AU - Sulyok, E.

AU - Lakatos, Orsolya

AU - Wittmann, I.

AU - Martens-Lobenhoffer, Jens

AU - Bode-Böger, Stefanie M.

PY - 2008/3

Y1 - 2008/3

N2 - Aims: To define the role of asymmetric dimethylarginine (ADMA) in the control of blood pressure (BP) during hemodialysis (HD). Methods:L-Arginine, ADMA and symmetric dimethylarginine (SDMA) levels of patients with (n = 18) or without (n = 13) hypotensive episodes during HD sessions were measured before and after HD treatment by liquid chromatography-mass spectrometry. Clinical variables, laboratory parameters and underlying pathologies of end-stage renal disease (ESRD) were comparable in the groups. BP was serially recorded. Results: In patients with ESRD, plasma dimethylarginines were markedly elevated and decreased significantly by the end of the HD sessions. ADMA levels in patients having hypotensive episodes during HD were significantly higher than in those maintaining their BP (before HD: 0.62 ± 0.11 μmol/l vs. 0.71 ± 0.13 μmol/l, p = 0.04; after HD: 0.31 ± 0.11 μmol/l vs. 0.43 ± 0.11 μmol/l, p = 0.01). There was a significant inverse relationship of the minimum systolic and diastolic BP during HD to the predialysis ADMA levels (for systolic BP r = -0.50, p <0.01; for diastolic BP r = -0.59, p <0.01) and to the postdialysis ADMA levels (for systolic BP r = -0.49, p <0.01; for diastolic BP r = -0.51, p <0.005), respectively. Conclusions: It is suggested that excessive NO generation is involved in the HD-associated hypotension and induces an increase in plasma ADMA levels to prevent further fall in BP.

AB - Aims: To define the role of asymmetric dimethylarginine (ADMA) in the control of blood pressure (BP) during hemodialysis (HD). Methods:L-Arginine, ADMA and symmetric dimethylarginine (SDMA) levels of patients with (n = 18) or without (n = 13) hypotensive episodes during HD sessions were measured before and after HD treatment by liquid chromatography-mass spectrometry. Clinical variables, laboratory parameters and underlying pathologies of end-stage renal disease (ESRD) were comparable in the groups. BP was serially recorded. Results: In patients with ESRD, plasma dimethylarginines were markedly elevated and decreased significantly by the end of the HD sessions. ADMA levels in patients having hypotensive episodes during HD were significantly higher than in those maintaining their BP (before HD: 0.62 ± 0.11 μmol/l vs. 0.71 ± 0.13 μmol/l, p = 0.04; after HD: 0.31 ± 0.11 μmol/l vs. 0.43 ± 0.11 μmol/l, p = 0.01). There was a significant inverse relationship of the minimum systolic and diastolic BP during HD to the predialysis ADMA levels (for systolic BP r = -0.50, p <0.01; for diastolic BP r = -0.59, p <0.01) and to the postdialysis ADMA levels (for systolic BP r = -0.49, p <0.01; for diastolic BP r = -0.51, p <0.005), respectively. Conclusions: It is suggested that excessive NO generation is involved in the HD-associated hypotension and induces an increase in plasma ADMA levels to prevent further fall in BP.

KW - Asymmetric dimethylarginine

KW - Hypotension

KW - Regular hemodialysis

UR - http://www.scopus.com/inward/record.url?scp=40449139663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40449139663&partnerID=8YFLogxK

U2 - 10.1159/000114451

DO - 10.1159/000114451

M3 - Article

C2 - 18230915

AN - SCOPUS:40449139663

VL - 108

JO - Experimental Nephrology

JF - Experimental Nephrology

SN - 0028-2766

IS - 2

ER -